Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 4/20 | 0.40 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | XIAP | P98170 | 1/20 | 0.34 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3314831 | 0.93 | TACR1 (0.41) | TACR1ELANEFKBP4LMNATRPV1 | |
| SCHEMBL1078320 | 0.89 | TACR1 (0.42) | TACR1FKBP4TRPV1MMP2HPGD | |
| SCHEMBL3513112 | 0.87 | FKBP4 (0.44) | TACR1FKBP4TRPV1HPGDSMN1; SMN2 | |
| SCHEMBL1088249 | 0.87 | TACR1 (0.41) | TACR1FKBP4LMNATRPV1HPGD | |
| SCHEMBL366333 | 0.87 | TACR1 (0.51) | TACR1FKBP4 | |
| SCHEMBL10401251 | 0.87 | TACR1 (0.39) | TACR1ELANEFKBP4LMNATRPV1 | |
| SCHEMBL4824283 | 0.86 | PDF (0.43) | TACR1FKBP4 | |
| SCHEMBL7235515 | 0.86 | TACR1 (0.41) | TACR1ELANEFKBP4LMNATRPV1 | |
| SCHEMBL4898024 | 0.86 | TACR1 (0.42) | TACR1FKBP4TRPV1MMP2HPGD | |
| SCHEMBL368075 | 0.85 | TACR1 (0.39) | TACR1FKBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150073125-A1 | RECOMBINANT PROBIOTIC BACTERIA FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD) AND IRRITABLE BOWEL SYNDROME (IBS) | UNIVERSITÉ PARIS CITÉ (FR) | 2015-03-12 | — | — | US | disclosed |
| US-20120195859-A1 | RECOMBINANT PROBIOTIC BACTERIA FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD) AND IRRITABLE BOWEL SYNDROME (IBS) | UNIVERSITE PARIS DIDEROT - PARIS 7 (FR) | 2012-08-02 | — | — | US | disclosed |
| EP-1858509-A4 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LTD (GB) | 2009-03-18 | — | — | EP | disclosed |
| EP-1858509-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006094003-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2006-09-08 | — | — | WO | disclosed |
| EP-1613319-A2 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004091613-A2 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |